Aliskiren Hemifumarate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317166

CAS#: 173334-58-2 (hemifumarate)

Description: Aliskiren hemifumarate is a direct renin inhibitor. Its indication is essential (primary) hypertension.

Chemical Structure

Aliskiren Hemifumarate
CAS# 173334-58-2 (hemifumarate)

Theoretical Analysis

MedKoo Cat#: 317166
Name: Aliskiren Hemifumarate
CAS#: 173334-58-2 (hemifumarate)
Chemical Formula: C30H53N3O6.1/2C4H4O4
Exact Mass:
Molecular Weight: 609.83
Elemental Analysis:

Price and Availability

Size Price Availability Quantity
10.0mg USD 340.0 2 Weeks
25.0mg USD 450.0 2 Weeks
Bulk inquiry

Related CAS #: 173334-57-1(free base)  

Synonym: Aliskiren hemifumarate; CGP 060536B; CGP-060536B; CGP060536B; Rasilez; SPP100; Tekturna

IUPAC/Chemical Name: (αS,γS,δS,ζS)-δ-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-γ-hydroxy-4-methoxy-3-(3-methoxypropoxy)-α,ζ-bis(1-methylethyl)-benzeneoctanamide, 2E-butenedioate


InChi Code: InChI=1S/2C30H53N3O6.C4H4O4/c2*1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36;5-3(6)1-2-4(7)8/h2*10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35);1-2H,(H,5,6)(H,7,8)

SMILES Code: COC1=C(OCCCOC)C=C(C[C@H](C(C)C)C[C@H](N)[C@@H](O)C[C@H](C(NCC(C)(C)C(N)=O)=O)C(C)C)C=C1.OC(/C=C/C(O)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 609.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Zeymer U, Dechend R, Riemer T, Deeg E, Senges J, Pittrow D, Schmieder R; 3A Registry Investigators. Two-Year Outcomes of Patients Treated With Aliskiren Under Clinical Practice Conditions: Non-Interventional Prospective Study. J Clin Hypertens (Greenwich). 2015 Nov 14. doi: 10.1111/jch.12725. [Epub ahead of print] PubMed PMID: 26567060.

2: Puri R, Nissen SE, Menon V, Shao M, Hsu A, Bakris GL, Kastelein JJ, Williams B, Armbrecht J, Brunel P, Kataoka Y, Nicholls SJ. Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. Atherosclerosis. 2015 Dec;243(2):553-9. doi: 10.1016/j.atherosclerosis.2015.10.019. Epub 2015 Oct 20. PubMed PMID: 26523993.

3: Krum H, McMurray JJ, Abraham WT, Dickstein K, Køber L, Desai AS, Solomon SD, Chiang Y, Gimpelewicz C, Reimund B, Ali MA, Tarnesby G, Massie BM; ATMOSPHERE Committees and Investigators. The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics. Eur J Heart Fail. 2015 Oct;17(10):1075-83. doi: 10.1002/ejhf.408. PubMed PMID: 26511146.

4: Jarvis SS, Okada Y, Levine BD, Fu Q. Central integration and neural control of blood pressure during the cold pressor test: a comparison between hydrochlorothiazide and aliskiren. Physiol Rep. 2015 Sep 14;3(9). pii: e12502. doi: 10.14814/phy2.12502. Epub 2015 Sep 15. PubMed PMID: 26465969; PubMed Central PMCID: PMC4600375.

5: Hu J, Zhang LC, Song X, Lu JR, Jin Z. KRT6 interacting with notch1 contributes to progression of renal cell carcinoma, and aliskiren inhibits renal carcinoma cell lines proliferation in vitro. Int J Clin Exp Pathol. 2015 Aug 1;8(8):9182-8. eCollection 2015. PubMed PMID: 26464664; PubMed Central PMCID: PMC4583896.

6: Zhang Y, Wang L, Song Y, Zhao X, Wong MS, Zhang W. Renin inhibitor aliskiren exerts beneficial effect on trabecular bone by regulating skeletal renin-angiotensin system and kallikrein-kinin system in ovariectomized mice. Osteoporos Int. 2015 Oct 6. [Epub ahead of print] PubMed PMID: 26439241.

7: Simeoni M, Nicotera R, Colao M, Citraro ML, Pelagi E, Cerantonio A, Comi N, Coppolino G, Fuiano G. Direct inhibition of plasmatic renin activity with aliskiren: a promising but under-investigated therapeutic option for non-diabetic glomerulonephritis. Int Urol Nephrol. 2015 Oct 5. [Epub ahead of print] PubMed PMID: 26438325.

8: Jumar A, Ott C, Kistner I, Friedrich S, Schmidt S, Harazny JM, Schmieder RE. Effect of aliskiren on vascular remodelling in small retinal circulation. J Hypertens. 2015 Dec;33(12):2491-9. doi: 10.1097/HJH.0000000000000735. PubMed PMID: 26398851.

9: Takei Y, Ichikawa M, Kijima Y. Oral direct renin inhibitor aliskiren reduces in vivo oxidative stress and serum matrix metalloproteinase-2 levels in patients with permanent atrial fibrillation. J Arrhythm. 2015 Apr;31(2):76-7. doi: 10.1016/j.joa.2014.07.002. Epub 2014 Aug 29. PubMed PMID: 26336535; PubMed Central PMCID: PMC4550121.

10: Chang TT, Wu TC, Huang PH, Lin CP, Chen JS, Lin LY, Lin SJ, Chen JW. Direct Renin Inhibition with Aliskiren Improves Ischemia-Induced Neovasculogenesis in Diabetic Animals via the SDF-1 Related Mechanism. PLoS One. 2015 Aug 25;10(8):e0136627. doi: 10.1371/journal.pone.0136627. eCollection 2015. PubMed PMID: 26305217; PubMed Central PMCID: PMC4549314.